NCT05777278 is a Phase 1, PHASE2 clinical trial of Savolitinib in Non-small Cell Lung Cancer, sponsored by The First Affiliated Hospital of Guangzhou Medical University.

Who is sponsoring NCT05777278?

NCT05777278 is sponsored by The First Affiliated Hospital of Guangzhou Medical University.

What drugs are being tested in NCT05777278?

Interventions in NCT05777278: Savolitinib, Docetaxel.

What condition does NCT05777278 study?

NCT05777278 studies Non-small Cell Lung Cancer.

Is NCT05777278 still recruiting?

NCT05777278 is currently recruiting now. Last updated 10 October 2023.

Last reviewed 2023-10-10 · How we verify

NCT05777278

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression

Recruiting now Phase 1, PHASE2 Last updated 10 October 2023

What this trial tests

Phase 1, PHASE2 trial testing Savolitinib in Non-small Cell Lung Cancer in 29 participants. Currently enrolling.

Timeline

26 July 2023

Primary endpoint
31 August 2027

31 August 2027

Quick facts

Lead sponsor	The First Affiliated Hospital of Guangzhou Medical University
Phase	Phase 1, PHASE2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	29
Start date	26 July 2023
Primary completion	31 August 2027
Estimated completion	31 August 2027
Sites	1 location across China

Drugs / interventions tested

Savolitinib — full drug profile →
Docetaxel (Docetaxel) — full drug profile →

Conditions studied

Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →

Sponsor

The First Affiliated Hospital of Guangzhou Medical University

Who can join

18 and older, any sex, with Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, pilot, single-arm, single-center study exploring the efficacy and safety of savolitinib plus docetaxel as second-line therapy in patients with MET overexpressed, EGFR/ALK/ROS1/MET ex14m-wildtype advanced NSCLC. Participants will receive treatment of docetaxel (60 mg/m2, ivgtt, q3w) in combination with savolitinib (300mg or 200mg according to safety run-in recommendation, p.o., BID) after informed consent signed. Treatment will continue until either objective disease progression, unacceptable toxicity occurs, consent is withdrawn, other discontinuation criterion is met, or study completion.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?
Spagnolo CC, Ciappina G, Giovannetti E, Squeri A, et al · · 2023 · cited 21× · PMID 37373267 · DOI 10.3390/ijms241210119
Targeted therapies in non-small cell lung cancer: present and future.
McLaughlin J, Berkman J, Nana-Sinkam P. · · 2023 · cited 11× · PMID 37675274 · DOI 10.12703/r/12-22
Targeting the MET gene: unveiling therapeutic opportunities in immunotherapy within the tumor immune microenvironment of non-small cell lung cancer.
Ye L, Wang W, Li H, Ji Y, et al · · 2024 · cited 5× · PMID 39483139 · DOI 10.1177/17588359241290733
Targeting MET in non-small cell lung cancer brain metastases: from molecular mechanism to precision therapy.
Wang X, Chi Y, Mu F, Mao H, et al · · 2026 · PMID 41981677 · DOI 10.1186/s12967-026-08077-2

Verify or expand the search:

Other trials of Savolitinib

Trials testing the same drug.

NCT06692491 — Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS · Phase 2 · not yet recruiting
NCT06563999 — Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations. · Phase 2 · recruiting
NCT06348355 — A Positron-emission Tomography Study to Determine Brain Exposure of [11C]Savolitinib in Healthy Volunteers · Phase 1 · completed
NCT05888207 — A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male Subjects · Phase 1 · completed
NCT05768360 — A Study to Assess the Effects of Savolitinib on the Pharmacokinetics of Digoxin, Rosuvastatin, Metformin, and Furosemide · Phase 1 · completed

Other recruiting trials for Non-small Cell Lung Cancer

Currently open trials in the same condition.

NCT07431827 — MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) · Phase 3 · recruiting
NCT05987956 — Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting
NCT07195695 — Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer Wit · Phase 3 · recruiting
NCT06686771 — Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer · Phase 3 · recruiting
NCT06477055 — The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer · recruiting

Other The First Affiliated Hospital of Guangzhou Medical University trials

Trials by the same sponsor.

NCT07413952 — Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases · Phase 2 · not yet recruiting
NCT07395375 — Non-intubated Versus Intubated Anesthesia for Thoracoscopic Sublobar Resection · NA · not yet recruiting
NCT07395362 — Hybrid Robot-Assisted Percutaneous Ablation and Non-Intubated VATS for Multiple Pulmonary Nodules · NA · not yet recruiting
NCT07395349 — Safety And Recovery Of Tubeless Strategy In Uniportal VATS Wedge Resection · NA · not yet recruiting
NCT07377916 — Clinical Study of SHR-A1811 Combined With Pertuzumab as Second-Line Therapy in Patients With HER2-Altered Advanced NSCLC · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05777278 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Guangzhou Medical University
Last refreshed: 10 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05777278.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing